You are here: Industry Insights > Novartis

News List

Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis worldpharmanews
September 12, 2018
Alcon, the global leader in eye care and a division of Novartis, today announced plans to locate its future global headquarters in the Canton of Geneva, Switzerland, following completion of its proposed spinoff from Novartis. Alcon's new global headquarte
Novartis to Divest Sandoz US Dermatology Business to Aurobindo americanpharmaceuticalreview
September 07, 2018
Novartis has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, to Aurobindo Pharma USA, for $0.9 billion of cash plus $0.1 billion of ...
Novartis to Divest Sandoz US Dermatology Business to Aurobindo americanpharmaceuticalreview
September 07, 2018
Novartis has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, to Aurobindo Pharma USA, for $0.9 billion of cash plus $0.1 billion of potential earn-outs.
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo worldpharmanews
September 07, 2018
Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, to Aurobindo Pharma USA Inc., for USD 0.9 billion of cash plus USD 0.1 billi
Novartis receives EC approval for Kymriah to treat two cancers pharmaceutical
August 29, 2018
The European Commission (EC) has granted approval for Novartis’ Kymriah to treat patients with B-cell acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL).
Novartis wins EU approval for blood cancer therapy Kymriah expressbpd
August 29, 2018
Novartis has received European approval for Kymriah, its gene-modifying therapy for blood cancer, but said its introduction would vary from country to country as the Swiss drugmaker works out payment details and builds manufacturing capacity.
Novartis' CAR-T Therapy Kymriah Receives EC Approval contractpharma
August 28, 2018
The European Commission (EC) has approved Novartis' Kymriah (tisagenlecleucel) for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory......
Novartis' investigational combo impresses in breast cancer sub-group pharmafile
August 27, 2018
Novartis has revealed positive new data for its investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) combined with fulvestrant in the treatment of breast cancer, demonstrating that the therapy met its primary endpoint.
Novartis’ PI3K drug hits goal in phase 3 breast cancer trial, laying groundwork for talks with regulators fiercebiotech
August 24, 2018
Novartis’ PI3K inhibitor BYL719 has met the primary endpoint in a phase 3 breast cancer trial. The hit on the progression-free survival endpoint sets Novartis up to start talking to regulators about getting the drug to market.
Novartis appoints new CEO for controversial Korean unit biospectrumasia
August 24, 2018
Previously, the Korean Ministry of Health and Welfare fined Novartis ~$50M and suspended reimbursement of Exelon and Zometa for three months.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page